A two-centre audit on changes in ejection fraction (EF) following sequential anthracycline chemotherapy and trastuzumab (T) in patients with HER2+early breast cancer (EBC).
Citation
A two-centre audit on changes in ejection fraction (EF) following sequential anthracycline chemotherapy and trastuzumab (T) in patients with HER2+early breast cancer (EBC). 2017, 32(Suppl 1): S128 The BreastJournal
The BreastDOI
10.1016/S0960-9776(17)30399-5Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0960977617303995Type
Meetings and ProceedingsLanguage
enISSN
09609776ae974a485f413a2113503eed53cd6c53
10.1016/S0960-9776(17)30399-5